David Chang and Arie Belldegrun (Endpoints file photo)

#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

It’s hard to make a big mark in the an­ti-BC­MA field.

The CAR-T JNJ-4528 from J&J and Chi­na’s Leg­end has been hog­ging the head­lines re­cent­ly with stel­lar re­sults for ad­vanced mul­ti­ple myelo­ma, steadi­ly ad­vanc­ing on the strug­gling ide-cel (bb2121) pro­gram from Bris­tol My­ers Squibb and blue­bird. And then there’s a pas­sel of ri­vals hus­tling up every­thing from CAR-Ts to bis­pecifics and AD­Cs.

But Al­lo­gene $AL­LO is try­ing hard to give them a run for the mon­ey.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.